A desire by pharmaceutical companies to concentrate their resources on marketing products, rather than discovery, development and production will drive global revenues for contract manufacturing and research to nearly $168bn by 2009. Of this, approximately 10% will be aimed at CMC work.
This is the conclusion of a soon-to-be-released report from Business Communications Co, which notes that the current market for contract services into the drug industry was $100bn in 2004 and will grow at an average annual rate of at least 11 per cent over the next five years.
However, R&D and marketing functions of major pharmaceutical companies are suffering from declining ‘productivity’. To date, the industry's main strategic response to this - M&A - has not been fully effective in addressing this dynamic.
Nevertheless, many predict that a 'networked' pharmaceutical model is the answer to the longer-term challenges faced by the industry. According to this business model, major pharmaceutical companies, which currently operate approximately 80% of activities
in-house, will eventually perform only 40% in-house.
The remaining 60% will be conducted externally via a carefully selected, risk-managed portfolio of straight outsourcing arrangements and strategic alliances.
In order to properly service it’s increasingly global customer base, Quay Pharmaceuticals is please to announce the recruitment of Business Development Managers and the establishment of contact facilities in Japan and the USA.
We are delighted to welcome Sansei Oka, who joins us as Business Development Manager, Japan. Sansei began his career in 1973 in drug development and formulation research with Nippon Roche KK, eventually becoming Business Unit Manager of their Pharmaceutical Division. He subsequently moved to Warner-Lambert KK and joined their global business development team. Until very recently Sansei was global marketing manager for Shionogi Qualicaps KK before joining Quay.
Quay’s Japanese contact details:
302 Nakamura Bldg., 2-7-14 Shibuya, Shibuya-Ku, Tokyo, 150-0002, Japan.
Tel: +81 3 5468 7440, Fax: +81 3 5468 7453, E-mail: oka.iptm@topaz.ocn.ne.jp
Confirmation of Quay Pharma's USA agent and contact details in next issue.
Via a variety of routes of administration, dosage forms can be radio-labelled with short half-life, gamma-emitting isotopes such as technecium, indium or samarium prior to administration and Quay Pharma have often been involved in the preparation of the initially ‘cold’ forms.
Based on this experience, we believe that this co-operation can be translated into real business synergies and as well as creating a competitive edge versus other CMC providers. We look forward to a successful future collaboration with our new colleagues at Bio-Images; they are Professor Howard Stevens, Professor Clive Wilson and Dr Bridget O’Mahony.
The new facility, totalling 8,000 sq.ft. of high specification office and laboratory accommodation, has also allowed the purchase of a new range of equipment to further expand Quay’s analytical and formulation services. This has begun with an LAF cabinet for non-sterile production of PK samples and additional HPLC diode array systems. New equipment will continue to be added until the end of the year.
Sadaf Anwar PhD - Formulation Scientist
Sadaf completed her PhD ‘Tablet disintegration in complex media’ at Manchester University. This was a collaborative project with AstraZeneca.
The research found that the choice of disintegration media greatly influences disintegration time, due to the properties of the selected media. Prior to this Sadaf studied Pharmaceutical and Chemical Sciences at Liverpool John Moores University.
Marc Owen - Formulation Scientist
Marc studied M.Chem. at University of Leicester from 1997 to 2001.
Marc has previously worked for well known pharmaceutical and large biotechnology companies.
He has experience of synthetic, medicinal and polymer chemistry, pharmaceutical formulation, and laboratory to manufacture scale-up.